The FDA Commissioner says that insurers can help biosimilar adoption by taking short-term financial losses over long-term drug savings. What else should they be doing?
The Biosimilars Forum, in partnership with Medicines for Europe, says the U.S. can look to European policy directives to advance the biosimilars market.
The falsehoods being spread about biosimilars that don’t match up with reality.
The FDA issued a lengthy statement on biosimilar naming conventions—but industry groups worry it could disincentivize biosimilar development.
Industry groups are calling for clear FDA guidance on language used by biologic originators to protect market share.
What the future of specialty drugs holds for healthcare.
The latest in RA therapies, and what you can expect from the pipeline.
Biosimilar drugs are poised to transform the cancer drug market—so why is uptake so slow?
As more biosimilar agents are approved by the FDA, biologic manufacturers are looking for unique ways to hold on to market share.
While still largely a new phenomenon, biosimilars are here to stay—and this year will only bring more of them to market.